The Filing Desk

MannKind

MNKD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MNKD · Last close · November 13, 2026
$4.13
Value MannKind yourself

MannKind's revenue rose 22.2% to $349 million in fiscal 2025. Its operating margin was 11.1%, down from 25.4% a year earlier. Free cash flow was $14 million, down 58.3%. The diluted share count rose 10.7%.

MannKind Corporation Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-073516 Updated
Revenue
$349M
22.2%
Operating margin
11.1%
14.3 pts
Net income
$6M
78.8%
Free cash flow
$14M
58.3%
Return on equity
—
 
Market cap
$1.3B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What MannKind does

MannKind is a drug company focused on diabetes, heart and kidney conditions, and rare lung diseases. In the United States it sells three products itself. Afrezza is inhaled insulin, taken from a small inhaler at the start of a meal, for adults with diabetes. Furoscix is a form of the diuretic furosemide, given under the skin at home with a wearable device, for fluid buildup in people with chronic heart failure or chronic kidney disease. V-Go is a disposable patch-like device that delivers insulin. MannKind bought Furoscix when it acquired scPharmaceuticals in October 2025.

MannKind also developed Tyvaso DPI, an inhaled powder for pulmonary arterial hypertension and related lung disease. Its partner, United Therapeutics, sells it. MannKind earns a royalty on those sales and also makes money by manufacturing the supply for United Therapeutics. Outside the US it uses regional partners; in December 2025 it shipped Afrezza to its partner in India, Cipla, for launch there.

The FDA was reviewing two requests when the report was filed: one to approve Afrezza for children and adolescents with diabetes, and one for a new autoinjector form of Furoscix. MannKind is also testing an inhaled powder form of nintedanib for a lung scarring disease called idiopathic pulmonary fibrosis, and a second molecule with United Therapeutics.

Its biggest risks, as it describes them

  • Its products may achieve only limited commercial success.
  • A large share of revenue could drop if United Therapeutics reduces its commercial emphasis on Tyvaso DPI.
  • Manufacturing problems, and suppliers that fail to deliver materials on time or to standard.
  • Insurers and other payers not covering its products, so they might not be prescribed or bought.
  • Possible losses, a need to raise more capital, and test results that may not support new products.
From MannKind's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share fell 37.4% a year and net income 28.8% a year, as new shares raised the share count by 241% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments204171295197171
Debt incl. finance leases38237837336355
Net debt (negative means net cash)17820778−161183
Net debt to EBITDA——5.9x−2.0x3.6x
Debt to equity—————
Interest coverage−3.1x−4.3x0.6x6.1x2.8x
Current ratio4.5x3.5x3.6x3.3x1.7x
Quick ratio4.4x3.2x3.3x2.9x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project MannKind's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of MannKind reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 96 of 94 of 9
Rule of 4095.2%55.0%26.1%
Altman Z''−18.67−22.33−11.89
Accruals ratio−11.9%−3.4%−2.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassFailPass
F-score7 of 96 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put MannKind side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MannKindFY2522.2%11.1%3.9%—3.6x4
Arcutis BiotherapeuticsFY2591.3%−3.2%−1.7%−16.9%—4Compare
CorMedixFY25617.0%48.2%55.4%—−0.9x—Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
EvolusFY2511.6%−11.0%−15.4%−47.2%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1751228636575100199286349
Revenue growth—−93.3%137.2%126.3%3.3%15.8%32.2%99.4%43.5%22.2%
Gross profit158−6843505984178268322
Research and development15149761220314666
Operating income67−108−77−45−48−47−6497339
Net income126−117−87−52−57−81−87−12286
Diluted EPS (US$)1.36−1.13−0.60−0.27−0.26−0.32−0.34−0.040.100.02
Diluted shares (millions)92104144196223249257267284314
Cash flow
Cash from operations−78−65−38−88−28−62−81344218
Capital expenditure1—03112842105
Free cash flow−79—−38−91−29−73−88−83314
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000001500348
Stock-based compensation557661213182124
Balance sheet at fiscal year end
Cash and short-term investments2344715067204171295197171
Debt incl. finance leases282410211912238237837336355
Total assets1078510894109321295475394792
Total liabilities291299283284289530546721473843
Shareholders' equity−184−215−175−190−180−209−250−246−79−51
Margins and ratios
Gross margin90.2%−46.7%30.4%68.2%76.8%77.7%84.0%89.5%93.9%92.3%
Operating margin38.5%−921.1%−274.9%−70.8%−73.5%−62.3%−64.3%4.4%25.4%11.1%
Net margin71.9%−999.0%−312.2%−82.3%−87.9%−107.3%−87.6%−6.0%9.7%1.7%
Free cash flow margin−45.3%—−136.7%−144.4%−44.4%−97.0%−88.5%−4.2%11.5%3.9%
Rule of 40 (growth + FCF margin)——0.5%−18.2%−41.1%−81.2%−56.2%95.2%55.0%26.1%
Return on capital——————————
Return on equity——————————
Return on assets107.7%−122.5%−90.5%−51.5%−56.6%−37.7%−28.4%−3.1%6.3%1.0%
Net debt to EBITDA0.1x——————5.9x−2.0x3.6x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: MannKind's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with MannKind.